Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma

Annals of Oncology

Volumn 24, Issue 12, 2013, Pages 2963-2967

  Pecuchet N ^a,b   Bigot, F ^a,b   Gachet, J ^a,b   Massard, C ^c   Albiges, L ^c   Teghom, C ^a   Allory, Y ^d   Mejean A ^a,b   Escudier, B ^c   Oudard, S ^a,b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d HENRI MONDOR HOSPITAL   (France)

Author keywords

Bevacizumab; Carboplatin; Cisplatin; Collecting duct carcinoma; Gemcitabine

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; GEMCITABINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG RESPONSE; DRUG WITHDRAWAL; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG EMBOLISM; LUNG METASTASIS; LYMPH NODE METASTASIS; MAINTENANCE CHEMOTHERAPY; METASTATIC COLLECTING DUCT CARCINOMA; MIDDLE AGED; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SCORING SYSTEM; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; COLLECTING DUCT CARCINOMA; GEMCITABINE;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, RENAL CELL; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84888782030     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt423     Document Type: Article

References (35)

1. Ljungberg B, Campbell SC, Cho HY et al. The epidemiology of renal cell carcinoma. Eur Urol 2011; 60: 615-621.
2. Eble JN, Sauter G, Epstein J et al. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC 2004; 1-79.
3. Fleming S, Lewi HJ. Collecting duct carcinoma of the kidney. Histopathology 1986; 10: 1131-1141.
4. Motzer RJ, Bacik J, Mariani T et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002; 20: 2376-2381.
5. Kafé H, Verbavatz J-M, Cochand-Priollet B et al. Collecting duct carcinoma: an entity to be redefined? Virchows Arch 2004; 445: 637-640.
6. Oudard S, Banu E, Vieillefond A et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study. J Urol 2007; 177: 1698-1702.
7. Hahn NM, Stadler WM, Zon RT et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol 2011; 29: 1525-1530.
8. Balar AV, Apolo AB, Ostrovnaya I et al. Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. J Clin Oncol 2013; 31: 724-730.
9. Barrascout E, Beuselinck B, Ayllon J et al. Complete remission of pulmonary metastases of Bellini duct carcinoma with cisplatin, gemcitabine and bevacizumab. Am J Case Rep 2012; 13: 1-2.
10. Motzer RJ, Bacik J, Murphy BA et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-296.
11. Heng DYC, Xie W, Regan MM et al. External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: a population-based study. Lancet Oncol 2013; 14: 141-148.
12. Srigley JR, Delahunt B. Uncommon and recently described renal carcinomas. Mod Pathol 2009; 22(Suppl 2):S2-S23.
13. Wright JL, Risk MC, Hotaling J et al. Effect of collecting duct histology on renal cell cancer outcome. J Urol 2009; 182: 2595-2599.
14. Méjean A, Roupret M, Larousserie F et al. Is there a place for radical nephrectomy in the presence of metastatic collecting duct (Bellini) carcinoma? J Urol 2003; 169: 1287-1290.
15. Karakiewicz PI, Trinh Q-D, Rioux-Leclercq N et al. Collecting duct renal cell carcinoma: a matched analysis of 41 cases. Eur Urol 2007; 52: 1140-1145.
16. Tokuda N, Naito S, Matsuzaki O et al. Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. J Urol 2006; 176: 40.-43.; discussion 43.
17. Kuroda N, Toi M, Hiroi M et al. Review of collecting duct carcinoma with focus on clinical and pathobiological aspects. Histopathology 2002; 17: 1329-1334.
18. Srigley JR, Eble JN. Collecting duct carcinoma of kidney. Semin Diagn Pathol 1998; 15: 54-67.
19. Kobayashi N, Matsuzaki O, Shirai S et al. Collecting duct carcinoma of the kidney: an immunohistochemical evaluation of the use of antibodies for differential diagnosis. Hum Pathol 2008; 39: 1350-1359.
20. Selli C, Amorosi A, Vona G et al. Retrospective evaluation of c-erbB-2 oncogene amplification using competitive PCR in collecting duct carcinoma of the kidney. J Urol 1997; 158: 245-247.
21. Fine SW, Argani P, DeMarzo AM et al. Expanding the histologic spectrum of mucinous tubular and spindle cell carcinoma of the kidney. Am J Surg Pathol 2006; 30: 1554-1560.
22. Gupta R, Billis A, Shah RB et al. Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship. Am J Surg Pathol 2012; 36: 1265-1278.
23. Calderaro J, Moroch J, Pierron G et al. SMARCB1/INI1 Inactivation in renal medullary carcinoma. Histopathology 2012; 61: 428-435.
24. Orsola A, Trias I, Raventós CX et al. Renal collecting (Bellini) duct carcinoma displays similar characteristics to upper tract urothelial cell carcinoma. Urology 2005; 65: 49-54.
25. Chao D, Zisman A, Pantuck AJ et al. Collecting duct renal cell carcinoma: clinical study of a rare tumor. J Urol 2002; 167: 71-74.
26. Dimopoulos MA, Logothetis CJ, Markowitz A et al. Collecting duct carcinoma of the kidney. Br J Urol 1993; 71: 388-391.
27. Peyromaure M, Thiounn N, Scotté F et al. Collecting duct carcinoma of the kidney: a clinicopathological study of 9 cases. J Urol 2003; 170: 1138-1140.
28. Mego M, Sycova-Mila Z, Rejlekova K et al. Sunitinib in the treatment of tubulocystic carcinoma of the kidney. A case report. Ann Oncol 2008; 19: 1655-1656.
29. Miyake H, Haraguchi T, Takenaka A et al. Metastatic collecting duct carcinoma of the kidney responded to sunitinib. Int J Clin Oncol 2011; 16: 153-155.
30. Staehler M, Schöppler G, Haseke N et al. Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase inhibition with sunitinib. Clin Genitourin Cancer 2009; 7: 58-61.
31. Molina AM, Feldman DR, Ginsberg MS et al. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Invest New Drugs 2010; 30: 335-340.
32. Tannir NM, Plimack E, Ng C et al. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol 2012; 62: 1013-1019.
33. Ansari J, Fatima A, Chaudhri S et al. Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney. Onkologie 2009; 32: 44-46.
34. Procopio G, Verzoni E, Iacovelli R et al. Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases. Clin Exp Nephrol 2012; 16: 464-467.
35. Bronchud MH, Castillo S, Escriva de Romani S et al. HER2 Blockade in metastatic collecting duct carcinoma (CDC) of the kidney: a case report. Onkologie 2012; 35: 776-779.